Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy
Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy
复制标题
DOI：
10.1159/000333273
复制
发表时间：
2011-12
期刊：
影响因子：
3.5
通讯作者：
Lei Yu;Z. Dai;Z. Wang;Jia Fan;Jian Zhou
中科院分区：
文献类型：
--
作者：
Lei Yu;Z. Dai;Z. Wang;Jia Fan;Jian Zhou
肝移植（LT）是治疗肝细胞癌（HCC）的一种可行的治疗选择。许多标准，如米兰标准和加州大学旧金山分校弗朗西斯科（UCSF）的标准，已经建立了选择肝癌患者谁站从LT受益的子集。然而，他们仍然不足以预测肝癌患者复发的高风险和选择那些在低风险。许多分子是识别HCC患者复发风险高或低的可能候选者，为考虑LT适应症提供了更广泛的视角。除了作为生物标志物外，它们中的大多数还在功能上参与了一些有助于HCC转移的重要途径。它们所构成的复杂网络显示了多通道、多步骤的肝癌转移过程，给肿瘤治疗带来了困难。鉴于一些分子靶向药物在治疗肝细胞癌或预防肝移植后肿瘤复发方面的疗效，本文还对新兴的分子靶向治疗进行了讨论。
Liver transplantation (LT) is a viable therapeutic option for hepatocellular carcinoma (HCC). Many criteria, such as the Milan criteria and the University of California at San Francisco (UCSF) criteria, have been established to select a subset of HCC patients who stand to benefit from LT. However, they are still insufficient for predicting HCC patients at high risk for recurrence and selecting those at low risk. Many molecules which are probable candidates for recognizing HCC patients at high or low risk for recurrence give a wider perspective to consider for LT indication. Besides working as biomarkers, most of them are also functionally involved in some important pathways which contribute to HCC metastasis. The complex network constituted by them shows a multichannel, multistep HCC metastatic process which indicates difficulty in tumor therapy. Given the efficacy of some molecular targeted drugs in the treatment of HCC or prevention of tumor recurrence after LT, the emerging molecular targeted therapy is also discussed in this review.